TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02380040

Intervention type: DEVICE
Intervention: PPG
Description: A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software

Intervention type: DEVICE
Intervention: PPG
Description: A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software

Intervention type: DEVICE
Intervention: PPG
Description: A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software

Intervention type: DEVICE
Intervention: PPG
Description: A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software
Study: NCT00122369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnotic Relaxation
Description: A research assistant read to the patient a self-hypnotic relaxation script while displaying empathic attention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empathic Attention
Description: A research assistant displayed defined behaviors of empathic attention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic Attention
Description: A research assistant displayed defined behaviors of empathic attention.
Study: NCT04000204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYAJOINT Plus
Description: 60 mg / 3 ml cross-linked hyaluronan, SciVision Biotech Inc.
Study: NCT00990314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium Modified Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium Modified Release
Study: NCT03114631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with tumor lysate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with MUC-1/WT-1 peptides
Study: NCT03617146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: The intervention will seek to help participants express their diabetes emotional needs and to work with them to figure out what can be done to meet those needs. Depending on the unique needs of each participant, the coaching approach for this study will include: improving motivation and self-efficacy for diabetes management using motivational interviewing and appreciative inquiry; building trust and rapport through mindful listening, open-ended inquiry, and perceptive reflections; and expressing empathy through nonviolent communication. Each participant will receive eight individual coaching sessions over a five month period. All coaching sessions will be delivered over the phone (i.e. telecoaching). The coaching intervention will be done by a certified health and wellness coach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Distress-specific Education
Description: A diabetes distress-specific education that explains what diabetes distress is, why it matters, and its four domains. In addition, the participant is given feedback on his or her distress score and advised on ways to deal with the areas of greatest distress. Participant is linked with resources to overcome any expressed needs. The education is provided by a trained medical assistant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Distress-specific Education
Description: A diabetes distress-specific education that explains what diabetes distress is, why it matters, and its four domains. In addition, the participant is given feedback on his or her distress score and advised on ways to deal with the areas of greatest distress. Participant is linked with resources to overcome any expressed needs. The education is provided by a trained medical assistant.
Study: NCT01088399

Intervention type: DRUG
Intervention: Somatropin (rDNA origin)
Description: Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
Study: NCT02825199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: capsule: 300mg caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non caffeine
Description: capsule: placebo (maize starch)
Study: NCT01549925

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Surgical resection
Description: standard surgical resection using clamps and surgical ligatures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LIGASURE
Description: resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
Study: NCT00400569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate (SU011248)
Description: For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
Study: NCT02459678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Adherence Package
Description: The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
Study: NCT01355692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd: YLF laser treatment
Description: grid selective retinal treatment
Study: NCT04520321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141)
Description: engineered FGF-1 delivered intracamerally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141)
Description: engineered FGF-1 delivered intracamerally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141)
Description: engineered FGF-1 delivered intracamerally
Study: NCT04000204

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durolane
Description: 60 mg / 3 ml cross-linked hyaluronan, Bioventus LLC.
Study: NCT02459678

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
Study: NCT01093911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP7657
Description: Ascending single doses of CDP7657

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 0.9% sodium chloride aqueous solution
Study: NCT01586819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: The botulinum toxin will be injected into the wrinkles crow's feet. The injections will take about 10 minutes to complete.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemical Peel Only
Description: After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution \[a combination of resorcinol (14g), salicylic acid (14g), and lactic acid (85%) in ethanol (95%)\] will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel \[35% Trichloroacetic acid\] will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water. Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.
Study: NCT01559012

Intervention type: DRUG
Group type: OTHER
Intervention: Clonidine
Description: transdermal clonidine patch 5 mg q. 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Clonidine
Description: transdermal clonidine patch 5 mg q. 5 days
Study: NCT03584087

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: TG 0 (0Hr)
Study: NCT04520321

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (placebo)
Description: Placebo
Study: NCT01177540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
Study: NCT03390881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting condition
Description: Subjects will fast over the whole experimental period (480 min)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar condition
Description: After a 2-h fasting state, subjects will ingest every hour a drink containing 70% carbohydrate, 15% fat and 15% protein and providing 1.5 X hourly resting energy requirement.
Study: NCT04979702

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will complete a 3-month exercise and physical activity intervention supported by online recourses
Study: NCT03390881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fat condition
Description: After a 2-h fasting state, subjects will ingest every hour a drink containing 70% fat, 15% carbohydrate and 15% protein and providing 1.5 X hourly resting energy requirement.
Study: NCT00648596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet by mouth 1 hour before sexual activity for 12 weeks
Study: NCT01571895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF2156A
Description: DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 \[CXCL8; formerly interleukin (IL)-8\] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
Study: NCT01442870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin
Study: NCT04979702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth technology assisted exercise counselling
Description: Participants will complete a 3-month exercise and physical activity intervention supported by online recourses, exercise counselling sessions and mHealth technology
Study: NCT03824743

Intervention type: DRUG
Intervention: Lactate Ringer
Description: Patients managed with Lactate Ringer and obstetric hemorrhage

Intervention type: DRUG
Intervention: Plasma-lyte
Description: Patients managed with Plasma-Lyte and obstetric hemorrhage
Study: NCT03584087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Duration of Terlipressin after EVL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Duration of Terlipressin after EVL
Study: NCT00047112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT04083807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TISSEEL Lyo
Description: The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression with surgical gauze pads
Description: Surgical 4x4 inches gauze pads
Study: NCT02919527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Myofascial-Release
Description: Self-Myofascial-Release performed at the anterior thigh

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Static Stretching performed at the anterior thigh
Study: NCT02819791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized conventional therapy alone
Description: Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized conventional therapy alone
Description: Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimized conventional therapy with therapeutic education
Description: The objectives of this therapeutic education program involve:~* learning objectives and acquisition of knowledge and self-care skills making the patient more autonomous and facilitating its adherence.~* the objectives of acquiring coping skills ( self-confidence , stress management , setting projects ) to improve their quality of life .~* the development objectives respects the relevant criteria of quality , realism and principle of educational progress.
Study: NCT03172572

Intervention type: PROCEDURE
Intervention: Minimally invasive pancreatoduodenectomy
Description: Laparoscopic, robot-assisted, or hybrid resection

Intervention type: PROCEDURE
Intervention: Open pancreatoduodenectomy
Description: Open resection
Study: NCT03706183

Intervention type: DIAGNOSTIC_TEST
Intervention: Ischemia-modified albumin
Description: The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ischemia-modified albumin
Description: The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hearing thresholds
Description: The hearing levels will be determined for each group.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hearing thresholds
Description: The hearing levels will be determined for each group.
Study: NCT00554372

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
Description: Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
Description: Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
Study: NCT01797913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine，1000mg/m2，ivgtt，DAY1\&DAY8
Study: NCT02171741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: continuous daily dosing for 20 or 13 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: single infusion on day 1
Study: NCT03524638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visbiome
Description: Colorectal surgery plus administration of Visbiome on post-operative day 2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colorectal Surgery
Description: Colorectal surgery alone
Study: NCT04115670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group of educational intervention on the neurophysiology of pain and physical exercises
Description: The physiotherapist of the institution will execute the intervention on the group:~* 3 first pedagogical sessions on the neurophysiology of pain, distributed: 1 group session, 1 individual session at home, 1 in a personal interview format. These 3 sessions will last 2 weeks to be completed.~* Afterward, the protocol of physical exercise training will begin, supervised by the same physiotherapist who carried out the three initial sessions. There will be 15 sessions of specific and individualized physical exercise, in small groups of maximum 5 people. The duration of this part will be 10 weeks, so that from week 1 to 5 is 2 times per week, and from week 6 to 10 just 1 time per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will follow its normal course of activity
Study: NCT01848132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
Study: NCT03524638

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colorectal Surgery
Description: Colorectal surgery alone
Study: NCT02819687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791
Study: NCT03854422

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left position
Description: colonoscopy will be performed in 3 different locations. Left position, the patient will be in the left-side position during the entire colonoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left supine position
Description: Colonoscopy in the Left supine position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dynamic position
Description: Colonoscopy in the Dynamic position
Study: NCT03821493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 10 mg tablets
Description: On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.~On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole Solution 200 mg
Description: Itraconazole 200 mg will be administered as 20 mL (10 mg/mL) oral solution once daily on Days 1-5 in Period 2.~On Day 4 of Period 2, co-administration of itraconazole 200 mg and PF-06651600 30 mg will occur. Itraconazole will be administered first followed by PF-06651600 tablets.
Study: NCT01017237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine 0.25 mg/ml administered i.v. following the dexmedetomidine loading dose and the midazolam.
Study: NCT02064881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin glycinate
Description: All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs)
Study: NCT01334203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranolazine
Description: Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day.
Study: NCT03379207

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose
Study: NCT00047112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study: NCT03379207

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose

Intervention type: OTHER
Intervention: Tracheal Aspirates
Description: Only for mechanically ventilated participants.

Intervention type: OTHER
Intervention: Tracheal Aspirates
Description: Only for mechanically ventilated participants.

Intervention type: OTHER
Intervention: Surplus of Broncho-alveolar lavage fluid
Description: Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion

Intervention type: OTHER
Intervention: Surplus of Broncho-alveolar lavage fluid
Description: Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion
Study: NCT05697887

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy
Study: NCT02790970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PReDicT Test
Description: PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.